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SUMMARY
Kidney-derived c-Kit1 cells exhibit progenitor/stem cell properties in vitro (self-renewal capacity, clonogenicity, and multipotential-
ity). These cells can regenerate epithelial tubular cells following ischemia-reperfusion injury and accelerate foot processes efface-
ment reversal in a model of acute proteinuria in rats. Several mechanisms are involved in kidney regeneration by kidney-derived c-
Kit1 cells, including cell engraftment and differentiation into renal-like structures, such as tubules, vessels, and podocytes. Moreover,
paracrine mechanisms could also account for kidney regeneration, either by stimulating proliferation of surviving cells or modulating
autophagy and podocyte cytoskeleton rearrangement through mTOR-Raptor and -Rictor signaling, which ultimately lead to morpho-
logical and functional improvement. To gain insights into the functional properties of c-Kit1 cells during kidney development, home-
ostasis, and disease, studies on lineage tracing using transgenic mice will unveil their fate. The results obtained from these studies
will set the basis for establishing further investigation on the therapeutic potential of c-Kit1 cells for treatment of kidney disease in
preclinical and clinical studies. STEM CELLS TRANSLATIONAL MEDICINE 2018;7:317–324
SIGNIFICANCE STATEMENT
The search for putative stem cells or precursors within the kidney has been the focus of extensive research. The identification
of a kidney progenitor/stem cell population would provide important biological insights and could therapeutically be used to
generate new tubular, glomerular, and vascular cells for treatment of kidney disease. Recent findings support that c-Kit1 cells
isolated from neonatal rat kidney represent a novel population of progenitor/stem cells. Therefore, c-Kit1 cells fulfill all of the
criteria as a true kidney progenitor/stem cell, including self-renewal capacity, clonogenicity, and multipotentiality. c-Kit1 cells
formed nephrospheres when plated at clonal density, and were positive for epithelial, endothelial, and neuronal markers. Fur-
thermore, c-Kit1 cells exhibit the potential to treat renal failure by multi-compartment engraftment (tubular, vascular, and glo-
merular) following acute ischemia-reperfusion injury. In acute proteinuria induced by puromycin aminonucleoside, c-Kit1 cell
treatment rescued podocyte disarrangement and accelerated foot process effacement reversal by modulating autophagy and
mTOR pathway. Taken together, these findings unravel important aspects of stem cell therapy.
INTRODUCTION
Kidney-derived stem cell populations detected during embryonic
and early post-natal periods are identified by the markers Six2 [1]
and Lgr5 [2]. However, these stem cell populations are not found
when kidney is fully developed and are not maintained through-
out adult life. Conversely, in other organs, such as gut and stom-
ach, adult stem cells are implicated in both homeostatic tissue
maintenance and functional restoration after injury [3, 4]. The
existence of putative progenitor/stem cell populations in the adult
kidney is, therefore, a subject of debate, and multiple hypotheses
have been described in the literature.
Accordingly, several studies analyzed the effect of cell labeling
by thymidine analogs to trace the fate of proliferating cells during
kidney homeostasis and injury. By definition, stem cells are undif-
ferentiated and slow cycling cells, as opposed to the bulk of cycling
cells that are transit amplifying and rapidly cycling cells. For exam-
ple, when kidney epithelial cells in the S3 segment of proximal
tubules were chased for 14 days after BrdU administration (a
marker of DNA duplication), 40% of these cells were in cell cycle
arrest in G1 phase and were cyclin D1 positive, although they
were rapidly recruited after injury [5]. Sequential labeling with thy-
midine analogs after acute ischemia-reperfusion injury, revealed
that intrinsic repair occurred mainly by self-duplication of
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PERSPECTIVES
surviving epithelial cells, and not by a population of slow cycling
cells, for example, resident progenitor/stem cells [6]. Additionally,
when parietal epithelial cells (PECs) were irreversibly labeled
before ischemia-reperfusion injury, the number of labeled cells
remained constant, but when PECs were labeled during injury,
that number increased, suggesting that any surviving tubular cell
contributed to kidney regeneration [7].
Regeneration of other adult cells, such as hepatocytes and
pancreatic islet cells, may also involve self-duplication of differen-
tiated cells instead of stem cell differentiation [8, 9].
However, cell labeling by thymidine analogs may have a time-
dependent effect. Thus, during 2-week chase period after BrdU
labeling, a population of label-retaining cells (LRC; slow-cycling
cells), defined as possible candidates of kidney-specific stem cells,
can undergo cell division during renal ischemia recovery and
replace injured cells [10]. Furthermore, 2-month chase period
after BrdU labeling disclosed LRCs in the interstitium and papilla
[11, 12]. Notably, kidney may harbor distinct populations of LRCs
that are regulated according to age, for example, in early and late
neonatal periods, LRCs are found predominantly in the papilla and
inner medulla, and during adult life, they are detected in the cor-
tex, although the outer medulla seems to harbor LRCs during all
stages [13]. Additionally, LRCs of the kidney papilla can migrate to
the upper papilla and form a compartment of rapidly proliferating
cells after ischemic injury in GFP-histone2B transgenic mice [14],
yet activating SDF-1/CXCR4 signaling [15].
Similar controversies are also present in glomerular compart-
ment regeneration. In podocyte injury models, extracted human
CD241CD1331PDX- progenitors contributed to kidney regenera-
tion following adriamycin injection [16]. However, genetic labeling
of these cells unraveled that their recruitment occurs mainly in
juvenile mice [17] and only a small fraction of these cells is
recruited to glomeruli in adult mice, even when glomerular hyper-
trophy is induced [18].
More recently, other lines of evidence support the notion that
renin lineage cells may enhance glomerular regeneration by func-
tioning as progenitors of podocytes in a model of podocyte deple-
tion using anti-podocyte antibody [19], although these cells also
exhibit limited regenerative potential in aging mice [20]. To pro-
vide further evidence that remission of glomerular disease in mice
with adriamycin nephropathy is associated with the generation of
novel podocytes, pharmacological approach using glycogen syn-
thase kinases 3-a and 3-b inhibitor increases podocyte regenera-
tion and promotes glomerular disease remission [21].
In line with those studies that investigated putative candidates
of kidney-derived progenitor/stem cell population, our group set
out experiments to identify that population in kidney during
development, and document their cardinal properties of progeni-
tor/stem cell population.
C-KIT CELL POPULATION IN THE KIDNEYS: A NOVEL POPULATION
OF TISSUE SPECIFIC PROGENITOR/STEM CELLS
The proto-oncogene c-Kit (CD117), encoded by a gene on human
chromosome 4, is a 145-kD type III tyrosine kinase transmem-
brane receptor that is allelic with the white spotting locus (W) on
mouse chromosome 5. c-Kit receptor belongs to the platelet-
derived growth factor and macrophage-colony stimulating factor
receptor subfamily [22]. The extracellular portion of c-Kit binds to
its ligand, known as stem cell factor (SCF) located on human
chromosome 12, and the intracellular domain contains the enzy-
matic kinase domain. c-Kit/SCF pathway is involved in transducing
important signals in a variety of normal physiological and patho-
genic processes related to cell survival and proliferation, migra-
tion, and differentiation [23]. That pathway is also crucial for the
development of hematopoiesis, melanocytes, and primordial
germ cells, yet is important in the development of many mamma-
lian cells and organs [24].
Studies in Rodents
Embryonic and Neonatal Data. During embryonic mouse kid-
ney development, c-Kit1 cells are detected in primordial struc-
tures, known as S-shaped bodies, a structure that gives rise to
glomeruli, proximal tubules, Henle’s loop, and distal tubules, and
play also a critical role in nephron number and ureteric bud (UB)
branching [25, 26]. Likewise, c-Kit expression was observed not
only in hemangioblasts and mesenchyma metanephric, but also in
UB-derived structures, such as epithelial cells of distal tubules,
collecting ducts, ureter and bladder of mice [24]. These findings
suggest that c-Kit can be a marker of a population with multipo-
tentiality capacity, at least within the kidneys.
Recently, our group reported that c-Kit1 cells isolated from
neonatal rat kidneys may represent a novel resident progenitor/
stem cell population [27].When c-Kit1 progenitor/stem cells were
sorted out from rat neonatal kidneys, we found that these cells
exhibited self-renewal capacity, clonogenicity, and multipotential-
ity in vitro, as shown in Figure 1. c-Kit1 progenitor/stem cells
were expanded over 100 passages, formed nephrospheres when
plated at clonal density in non-adherent conditions, differentiated
into mesodermic (adipogenic, osteogenic, epithelial, and endothe-
lial) and ectodermic (neuronal) progeny, and were maintained
throughout adult life. Neonatal c-Kit1 nephrospheres were
observed at higher frequency when compared to adult c-Kit1
nephrospheres (e.g., 2.5% vs. 0.4%). To note, those cells started to
express angiotensin II type 1a receptor upon endothelial differen-
tiation and released calcium from endoplasmic reticulum via IP3
receptors. They also exhibited distinct responses to endothelin,
prostaglandin, and bradykinin when grew in endothelial medium.
Furthermore, c-Kit1 stem cells were able to treat renal failure by
multi-compartment engraftment, for example, tubular, vascular,
and glomerular following acute ischemia-reperfusion injury [27].
In a model of acute proteinuria induced by puromycin amino-
nucleoside (PAN), c-Kit1 progenitor/stem cells contributed to
improve foot process effacement, not only by paracrine mecha-
nisms, such as growth factors production and modulation of
autophagy and mTOR pathway, but also by engrafting into tubule-
interstitial compartment and differentiating into podocyte-like
cells [28].We observed that c-Kit1 progenitor/stem cell treatment
activated autophagy, an important intracellular degradation sys-
tem that maintains homeostasis by removing damaged protein
and organelles. The number of autophagosomes and autophagoly-
sosomes increased in a time-dependent manner in the c-Kit
treated animals, as well as the expression of autophagy marker
microtubule-associated protein light chain 3-II. Therefore, autoph-
agy activation contributed to foot processes reorganization. We
also found that autophagy activation was associated with mam-
malian target of rapamycin complex 1 (mTORC1) downregulation
on Ser 2448, as demonstrated by others in the kidney [29, 30]. In
addition, c-Kit treatment up regulated mTORC2-Rictor on Ser
2481, a rapamycin insensitive regulator of actin cytoskeleton [31],
which potentially targeted A-Actinin-4 in podocytes. Our results
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suggest that c-Kit1 progenitor/stem cell treatment can ultimately
rescue podocyte disarrangement and accelerate foot processes
effacement reversal [28].
Moreover, further studies are warranted to evaluate the
underlying pathophysiological mechanisms of c-Kit1 progenitor/
stem cell treatment on chronic kidney diseases (CKD).
Although less than 10% of the injected cells exhibited tissue
engraftment in acute ischemia-reperfusion and PAN-induced pro-
teinuria, these findings provide initial evidence that c-Kit based
cell therapy is promising due to its differentiation capacity [27,
28]. Figure 2 is a representative cartoon of c-Kit progenitor/stem
cell treatment and regenerative capacity in different models of
acute kidney injury.
To investigate further KIT function, a mutation introduced by
gene targeting at the W/Kit locus in mouse embryonic stem cells,
specifically marked c-Kit expressing cells and their fate was fol-
lowed during embryogenesis [24]. Of importance, melanoblasts,
primordial germ cells and hematopoietic progenitor cells failed to
survive in the absence of KIT, while endothelial, epithelial, and
endocrine cells did not depend on KIT expression for their migra-
tion, proliferation or survival during embryogenesis. Therefore, we
anticipate that KIT gene expression is only required for the normal
postnatal development of kidney-derived c-Kit progenitor/stem
cells described by our group.
Adult Data. The involvement of c-Kit1 progenitor/stem cells in
adult kidney homeostasis, disease, and regeneration was also
observed by others in rodent models, such as the juxta-
glomerular c-Kit1 cell recruitment after 10 day-period treatment
with low-salt and captopril (angiotensin-converting enzyme inhibi-
tor) [32], and the shift of c-Kit1 cells from the papilla and medul-
lary rays to the corticomedullar area following acute ischemia-
reperfusion injury [33].
In line with these findings, comprehensive lineage tracing is
essential to understand c-Kit cell fate during kidney development,
homeostasis, and disease. Stem cell dynamics can be studied with
single-clone resolution and the advent of multicolor reporter
alleles [34]. This approach enables examination of the individual
behavior of multiple stem cells in a single niche. To gain insights
into the division dynamics of resident stem cells of intestinal
crypts, studies in multicolor Cre-reporter mice unveiled that stem
cells double their numbers each day and stochastically adopt stem
or transient amplifying fates, and do not exhibit hierarchical or
asymmetric division [3].
More recently, continuous tubulogenesis in kidney adult mice
was documented to occur by fate-restricted precursors function-
ing as unipotent progenitors when single clones were analyzed in
multicolor mice [35]. Conversely, multiple adult nephron progeni-
tor/stem cells that reside throughout the zebrafish kidney contrib-
ute to a single nephron [36]. Likewise, a subpopulation of label
retaining cells localized in the upper papilla within the kidneys
possesses the capacity to proliferate and differentiate into distinct
tubular segments (proximal and distal tubules and Henle’s loop)
when a severe injury was established [37]. These results suggest
Figure 1. c-Kit1 cells exhibit progenitor/stem cell cardinal proper-
ties. c-Kit1 progenitor/stem cells are self-renewing, clonogenic, and
multipotent. These cells can be expanded over 100 passages, form
nephrospheres when plated at clonal density in non-adherent con-
ditions, and differentiate into mesodermic (adipocytic, osteogenic,
epithelial, and endothelial-like cells) and ectodermic (neuronal-like
cells) progeny. c-Kit1 progenitor/stem cells started to express angio-
tensin II type 1a receptor upon endothelial differentiation and
released calcium from endoplasmic reticulum via IP3 receptors. They
also exhibited distinct responses to endothelin, prostaglandin, and
bradykinin when grew in endothelial medium.
Figure 2. c-Kit1 progenitor/stem cells contribute to kidney regen-
eration following acute injury. c-Kit1 progenitor/stem cells can
regenerate epithelial tubular cells following ischemia-reperfusion
injury and accelerate foot processes effacement reversal in a model
of acute proteinuria in rats. These cells engraft and differentiate into
renal structures, such as tubules, vessels, and podocyte-like cells.
Paracrine mechanisms could also account for kidney regeneration,
either by stimulating proliferation of surviving cells or modulating
autophagy and podocyte cytoskeleton rearrangement through
mTOR-Raptor and- Rictor signaling, which ultimately lead to mor-
phological and functional improvement. Abbreviations: BUN, blood
urea nitrogen; mTORC2, mammalian target of rapamycin complex 2;
PAN, puromycin aminonucleoside.
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that different compartments of the kidney may have different pro-
genitor cell pools. Other organs, such as pancreas, may also harbor
multipotent precursors [38]. To determine whether kidney c-Kit1
cells represent a unipotent progenitor population or a multipotent
progenitor population in vivo, further lineage tracing analyses are
required to clarify that question.
Studies in Humans
Embryonic and Fetal Data. In humans, embryonic stem cells
also express c-Kit receptor [39] and in fetal kidney, c-Kit1 cells are
found at moderate levels in epithelial cells of the proximal tubule
and Henle’s loop, at weak and focal levels in distal tubules, and
were negative in renal corpuscules and collecting tubules [40].
Conversely, other authors reported the absence of c-Kit cells in
human fetal kidneys [41]. c-Kit1 cells represent 1% of human
amniotic fluid cells and exhibit stem cells properties, such as clo-
nogenicity and multipotentiality [42]. Of importance, considering
that human amniotic fluid harbor kidney epithelial tubular cells
that were detached from embryonic and fetal kidneys and that
these cells repair mice kidney after ischemia-reperfusion injury
[43], we believe that these results should be considered as sup-
porting information of our results.
Therefore, the evaluation of c-Kit expression at different time
points of human embryonic and fetal nephrogenesis is lacking in
the literature and the role of c-Kit cells during kidney development
requires further investigation.
Adult Data. c-Kit expression is also maintained in human adult
kidney and is expressed at moderate levels in the cytoplasm of
proximal and distal tubules [40]. However, others reported
absence of c-Kit1 cells in adult kidneys [44] kidneys. This contro-
versial data can be attributed to different techniques of c-Kit
detection using paraffin-embedded samples.
c-Kit label using rabbit polyclonal antibody (DAKO, Glostrup,
Denmark) was verified in both cortex and medulla tubules in
healthy individuals and deceased donors with acute tubular
necrosis (Fig. 3).
Based on cross-species conservation, we speculate if human
adult and fetal kidneys harbor a population of c-Kit1 progenitor/
stem cells that exhibit clonogenicity, self-renewal capacity, multi-
potentiality, and regenerative potential. The results obtained from
this approach will set the basis for establishing further investiga-
tion involving the therapeutic potential of c-Kit1 cells for treat-
ment of kidney disease in preclinical and clinical studies.
Furthermore, we are currently working on c-Kit cell isolation
from human kidney biopsies.We have already performed 12 flow
cytometry analyses of eight kidney deceased donors (all male,
mean age of 206 15.6 years-old, ranging from 2 to 46 years-old,
and non-cardiovascular cause of brain death in 70% of the individ-
uals). In Figure 4A, a human kidney biopsy was obtained from a
deceased donor, 36-year, with brain trauma. c-Kit cells were sorted
out by flow cytometry and successfully expanded. c-Kit cells were
found to be positive in 3.6%6 3% of the kidney cells before sort-
ing in human kidney biopsies obtained from deceased donors (Fig.
4B). The positive fraction for c-Kit cells that were sorted out exhib-
ited 92%6 5.8% positivity for c-Kit while the negative fraction
exhibited negativity for c-Kit in 98.3%6 1.6% of the cells (Fig. 4C).
By qPCR, positivity for c-Kit was also higher in the c-Kit positive
fraction (Fig. 4D).
Of importance, understanding KIT gene regulation will provide
insightful evidence of progenitor/stem c-Kit population within the
kidneys. KITmutation or activation is a major pathogenic event in
certain tumors. Pathological activation of KIT through gain-
function mutations leads to neoplasia in different systems: mast
cells/myeloid cells (mastocytosis/acute myeloid leukaemia), germ
cells (seminoma), and Cajal cells (gastrointestinal stromal tumors)
[45]. In renal tumors, most conventional renal cell carcinomas
(RCC) are c-Kit negative, although a subset of clear cell, papillary
type and chromophobe RCCs, all oncocytomas, and most meso-
blastic nephromas are c-Kit positive [40]. Notably, c-Kit localization
in chromophobe RCC is not homogenous and can be found in
cytoplasmic, membranous and nuclear compartments [46].
In the paediatric Wilms tumor (nephroblastoma), c-Kit expres-
sion is very rare (0%–4%), but when that mutation is detected,
relapse can occur at a shorter time [40, 47].
Of importance, KIT mutations do not correlated to KIT copy
number or CD117 expression in different neoplasias [48, 49].
Dysregulation of c-Kit expression may be attributed to DAB2IP,
a novel Ras-GTPase activating protein frequently found in many
cancer types and associated with cancer stem cells properties
[50]. SCF induces activation of phosphatidylinositol (PI) 3-kinase-
Akt and subsequent phosphorylation of Bad, a pro-apoptotic mol-
ecule, on Ser112 and Ser136 [51]. DAB2IP can suppress c-Kit gene
expression and c-Kit-PI3K-Akt-mTOR signaling pathway that
increases c-myc protein, which leads to activate ZEB1 gene expres-
sion and therefore to cancer stem cell phenotypes [50]. Likewise,
DAB2IP knockout (KO) mice exhibit elevated expression of ZEB1
and CD117 in the prostate basal cell population.
Whether those signaling pathways are involved during devel-
opment or adult kidneys or during homeostasis or disease, critical
analyses are further required.
In benign conditions, such as piebaldism, an autosomal domi-
nant disorder characterized by congenital patches of white skin
and hair that lack melanocytes, the phenotypic severity of the dis-
ease correlates with the site and the type on the KIT gene [52]. A
similar disorder of mouse, dominant white spotting (W) results
from mutations of the c-Kit proto-oncogene and may serve as a
disease model of human piebaldism.
Figure 3. c-Kit cell immunochemistry in human kidneys. c-Kit cells
are found in both cortex and medulla epithelial tubular cells from
kidney biopsies of healthy individuals and deceased donors with
acute tubular necrosis. Scale bars represent 50 lm for immunohis-
tochemistry images.
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C-KIT1 CELL POPULATION IN OTHER ORGANS
c-Kit receptor expression is also constitutionally expressed in dif-
ferentiated cells that do not exhibit stem cell properties, such as
mast cells, germ cells, melanocytes, gastrointestinal Cajal cells,
fetal endothelial cells, and epithelial cells, including breast ductal
cells, oesophageal and sweat glands, parotid, some cells of skin
adnexa, and neurons of cerebellum, hippocampus, and spinal dor-
sal horn [44, 45].
However, c-Kit1 cells are reported as a population of progeni-
tor/stem cells in many organs and tissues, as documented in
bone-fide studies. In these studies, similarly to our findings, c-Kit1
cells differentiated into endothelial, epithelial, and neuronal-like
cells.
In bone marrow, c-Kit signaling is involved in cellular adhesion
and is essential for long-term maintenance and expansion of
hematopoietic progenitor/stem cells [53]. In liver, human c-Kit1
cells are occasionally found in the biliary duct and in close proxim-
ity to biliary epithelial cells and, when sorted out, these cells can
form epithelial and endothelial colonies in vitro [54]. In heart, c-
Kit1 cells exhibit stem cells properties in vitro [55] and promote
cardiac repair after myocardium infarction [56]. To note, c-Kit1
cells generate cardiac endothelial cells in vivo as demonstrated by
lineage tracing in mice [57]. In lungs, human c-Kit1 cells partici-
pate in tissue homeostasis and regeneration, giving rise to bron-
chioles, alveoli, and pulmonary vessels [58]. Likewise, c-Kit1 cells
are detected in murine epithelia of sub-mandibular gland during
embryonic and post-natal periods, and are involved in the growth
of ductal and acinar cells during development [59]. In olfactory
neuroepithelial injury, c-Kit1 progenitor cell population, that
resides among the globose basal cell populations, is activated to
reconstitute the neuronal population [60].
Although kidney-derived c-Kit1 cells share some similar-
ities with c-Kit1 cells from other organs, for example, the
capacity to differentiate into endothelial and epithelial prog-
eny, it has not been elucidated whether these cells come from
the same unipotent precursor or from multipotent precursors,
yet c-Kit1 cells are detected in tissues originated from all three
germ layers.
In all these studies, staining for mast cells markers, such as
CD14 and mast cell tryptase, are crucial for differentiation from
mast cells and for understanding the biological properties of c-
Kit1 cells [61].
FUTURE DIRECTIONS IN KIDNEY REGENERATION: NOVEL
THERAPIES AND TRANSLATIONAL ASPECTS OF C-KIT1
PROGENITOR/STEM CELLS
CKD is a worldwide public health problem that affects millions of
people from all age, racial, and ethnic groups. CKD is incurable,
requiring renal replacement therapy, that is, dialysis or preferably
renal transplantation. However, the critical shortage of available
organs for transplantation continues to severely limit this option,
underlying the importance of novel therapeutic regimens, such as
stem cell therapy [62].
Current approaches include the understanding of kidney
disease and development using genome and tissue engineer-
ing in human pluripotent stem cells (hPSCs) [63, 64]. hPSCs,
including human embryonic stem cells and human induced
pluripotent stem cells, can be differentiated toward kidney
organoids using small molecules and soluble factors mimicking
the signals triggering kidney development in vivo. These hPSCs
can be directed to intermediate mesoderm, the embryonic lin-
eage giving rise to both UB and metanephric mesenchyme
progenitors.
In addition, genome engineering can be efficiently achieved in
hPSCs using CRISPR/Cas9, which is composed by a nuclease Cas9
Figure 4. c-Kit cells are found in human kidneys. (A): A human kidney biopsy was obtained from a male deceased donor, 36-year, with brain
trauma. c-Kit cells were sorted out by flow cytometry and successfully expanded for several days (D). (B): c-Kit cells were found to be positive
in 3.6%6 3% of the kidney cells before sorting in human kidney biopsies obtained from deceased donors (n5 12 analyses in eight human
kidney donors). (C): The positive fraction for c-Kit cells that were sorted out exhibited 92%6 5.8% positivity for c-Kit while the negative frac-
tion exhibited negativity for c-Kit in 98.3%6 1.6% of the cells. (D) By qPCR, positivity for c-Kit was also higher in the c-Kit positive fraction.
Scale bars represent 20 lm for (A) images.
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and a small guide (sg) RNA determining binding specificity trough
base pairing to its genomic target [63]. This approach allows intro-
ducing any modification useful for disease modeling and develop-
mental studies in hPSCs including, single and multiple KO or
knockin mutations; creation of doxycycline-, CRE- or FLP inducible
KO lines; reporters and lineage tracer lines; and performing
genetic screenings using Cas9 and pooled sgRNA libraries.
Kidney organoids-derived form nephron progenitors and
hPSCs can not only be tested for disease modeling and subse-
quent drug screening and toxicity testing, but also contribute to
bioengineered kidney design and kidney regeneration [64–66]. In
line with these perspectives, developing strategies to recreate the
niche of nephron progenitor cells, such as 3D culture, and under-
stating the signaling pathways will allow those cells to maintain
genomic stability, molecular homogeneity, clonogenicity, differen-
tiation potential, self-renewal capacity, and nephrogenic potential
[66, 67].
To note, identification of progenitor/stem cell populations in
mammalian tissues is also important for therapeutic applications,
and for understanding developmental processes and tissue home-
ostasis. Furthermore, pursuing progenitor/stem cell-based kidney
regenerative strategies is also a key step toward the development
of a bioengineered transplantable kidney [68].
Sorting out c-Kit1 progenitor/stem cells from human adult kid-
neys and growing these cells as adherent cells or nephrospheres
are promising therapeutic strategies. Although human fetal kid-
neys may harbor a c-Kit1 progenitor/stem cell population, ethical
aspects require further discussion. Of importance, some considera-
tions of preclinical studies using kidney-derived c-Kit1 stem/pro-
genitor cells need to be highlighted, as proposed by others [69]:
a. Selection of the animal model (species, immunocompetent
or immunocompromised, diseased or healthy animals, acute
and chronic models, and feasibility of cell injection);
b. Design considerations (the model should mimic the intended
clinical application as closely as possible and cell product
manufacturing should be comparable to the intended clinical
methods);
c. Proof-of-concept studies (endpoints should include survival,
functional and morphological parameters, cell engraftment,
durability of the response);
d. Biodistribution studies (analyses of chronic and acute time
points and dose/route of administration, number of injec-
tions, which should mimic intended clinical use) and
e. Safety studies (dose raging, short- and long-term toxicity,
and tumorogenicity).
CONCLUSION
Current kidney regeneration approaches include the understand-
ing of kidney disease and development using genome and tissue
engineering in hPSCs. These cells can be tested for disease model-
ing and ultimately be differentiated toward kidney organoids mim-
icking the signals triggering kidney development in vivo, and
contribute to bioengineered kidney design.
c-Kit1 cells may represent a novel population of kidney-derived
progenitor/stem cells found during kidney development that are
also maintained throughout adult life. These cells contribute to kid-
ney regeneration following injury. Of importance, the identification
of kidney-specific population of progenitor/stem cells will abbrevi-
ate the need of direct differentiation into renal structures.
However, studies with multicolor mice and lineage tracing will
unveil c-Kit1 cells dynamics during kidney development, homeo-
stasis, and disease. Therefore, these studies possess important
biological and therapeutic applications. Based on cross-species
conservation, further studies in development and adult human
kidneys will also establish the basis for treatment of kidney dis-
ease in preclinical and clinical studies.
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